Topics

EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo

06:00 EDT 26 Apr 2019 | PharmaNews.EU

EMAEMA has completed its assessment of the results of the ANNOUNCE study and concluded that Lartruvo (olaratumab) with doxorubicin does not prolong the lives of patients with soft tissue cancer more than doxorubicin alone. The Agency is therefore recommending that the marketing authorisation of the medicine be revoked.

Original Article: EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo

NEXT ARTICLE

More From BioPortfolio on "EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo"

Quick Search

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...